AU1953995A - Recombinant antibody fragments which are synthesized and biotinylated in e. coli, their use in immunoassays and immunopurification techniques - Google Patents

Recombinant antibody fragments which are synthesized and biotinylated in e. coli, their use in immunoassays and immunopurification techniques

Info

Publication number
AU1953995A
AU1953995A AU19539/95A AU1953995A AU1953995A AU 1953995 A AU1953995 A AU 1953995A AU 19539/95 A AU19539/95 A AU 19539/95A AU 1953995 A AU1953995 A AU 1953995A AU 1953995 A AU1953995 A AU 1953995A
Authority
AU
Australia
Prior art keywords
immunoassays
biotinylated
coli
synthesized
antibody fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19539/95A
Inventor
Jean Chatellier
Georges Orfanoudakis
Etienne Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Louis Pasteur Strasbourg I
Original Assignee
Universite Louis Pasteur Strasbourg I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Louis Pasteur Strasbourg I filed Critical Universite Louis Pasteur Strasbourg I
Publication of AU1953995A publication Critical patent/AU1953995A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU19539/95A 1994-03-17 1995-03-13 Recombinant antibody fragments which are synthesized and biotinylated in e. coli, their use in immunoassays and immunopurification techniques Abandoned AU1953995A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9403125A FR2717499B1 (en) 1994-03-17 1994-03-17 Fragments of recombinant antibodies synthesized and biotinylated in E. coli, their use in immunoassays and in purification by immunoaffinity.
FR9403125 1994-03-17
PCT/FR1995/000293 WO1995025172A1 (en) 1994-03-17 1995-03-13 Recombinant antibody fragments which are synthesized and biotinylated in e. coli, their use in immunoassays and immunopurification techniques

Publications (1)

Publication Number Publication Date
AU1953995A true AU1953995A (en) 1995-10-03

Family

ID=9461144

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19539/95A Abandoned AU1953995A (en) 1994-03-17 1995-03-13 Recombinant antibody fragments which are synthesized and biotinylated in e. coli, their use in immunoassays and immunopurification techniques

Country Status (3)

Country Link
AU (1) AU1953995A (en)
FR (1) FR2717499B1 (en)
WO (1) WO1995025172A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021156A1 (en) * 1995-01-04 1996-07-11 Abbott Laboratories Method for preparing scintillation proximity assay targets
EP1211514A4 (en) * 1999-08-31 2005-03-09 Mitsubishi Chem Corp Method of analyzing mutual interaction between protein and molecule
ATE356874T1 (en) 1999-12-22 2007-04-15 Dade Behring Marburg Gmbh HUMAN PROCALCITONIN SOLUTIONS
EP1110970B1 (en) 1999-12-22 2008-05-14 Dade Behring Marburg GmbH Anti-Procalcitonin antibodies, their production and use
FR2816943B1 (en) * 2000-11-22 2004-02-13 Inst Nat Sante Rech Med BIOTIN DERIVATIVES, METHODS OF MAKING SAME AND USES THEREOF AS VECTORS
DE10064827A1 (en) 2000-12-22 2002-06-27 Dade Behring Marburg Gmbh Sandwich assay for detecting analyte, useful e.g. for hormones, with detection or correction of the hook effect by measuring detection signals twice
GB0202018D0 (en) * 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
WO2005062048A1 (en) 2003-12-01 2005-07-07 Dade Behring Marburg Gmbh Homogeneous detection method
DE102005026163A1 (en) 2004-08-24 2006-03-02 Dade Behring Marburg Gmbh Antibodies directed against the Marburg I polymorphism of Factor VII activating protease (FSAP), their production and use
DE102005022047A1 (en) 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Binding partner of the placental growth factor, in particular antibodies directed against the placental growth factor, their production and use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472658A4 (en) * 1989-05-19 1992-08-26 Biotechnology Res & Dev Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification

Also Published As

Publication number Publication date
FR2717499B1 (en) 1996-05-24
WO1995025172A1 (en) 1995-09-21
FR2717499A1 (en) 1995-09-22

Similar Documents

Publication Publication Date Title
AU1914595A (en) Isolated antigenic oncogene peptide fragments and uses
AU6267896A (en) Antibody and antibody fragments for inhibiting the growth oftumors
HUP9802217A3 (en) Recombinant mva virus, and the use thereof
AU6515499A (en) Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
AU7398200A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU2455295A (en) Protein or polypeptide, process for producing the same, and intermediate compound tehrefor
GB9614700D0 (en) Over-expression of proteins in E.Coli
AU1953995A (en) Recombinant antibody fragments which are synthesized and biotinylated in e. coli, their use in immunoassays and immunopurification techniques
AU3381097A (en) Tumor necrosis factor-related polypeptide
AU2138501A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU3003095A (en) Proteins associated with tumor necrosis factor receptor
HUP9904199A3 (en) Anti-p53 single-chain antibody fragments and their uses
AU4373197A (en) Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
AU3451397A (en) Modified protein g and fragments thereof
AU1283400A (en) Protein fragments for use in protein targeting
AU5878398A (en) Evaporator making method, such evaporator and use thereof
AU5137698A (en) Novel dna, novel protein, and novel antibody
AU1693995A (en) Phosphacan, nucleic acids encoding thereof and antibodies thereto
AU2138601A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU4219397A (en) Novel protein, its production and use
AUPO169396A0 (en) Improvements in refrigeration control
WO1997039623A3 (en) Improved production of insecticidal proteins
AU1375501A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2003252758B2 (en) Antibody variants and fragments thereof
AU6001499A (en) Tumor-specific antigen peptides